SHANGHAI – KBP Biosciences (China) Inc. is the brainchild of Zhenhua Huang, a Chinese serial entrepreneur that first found success with his earlier effort, Xuanzhu Pharma. Huang is a rare breed of biotech founder, China-born and educated, he has an international vision for KBP building on the lessons learned from more than a decade of doing business in China.
Sciclone Pharmaceuticals Inc. has wound down a strategic review process after having spoken with a number of potential buyers, deciding instead to remain a publicly listed company. The company said the board did not receive a bid that reflected a premium to the company's trading price. Sciclone plans to continue with growth plans for its China-focused commercial business.
Sciclone Pharmaceuticals Inc. has wound down a strategic review process after having spoken with a number of potential buyers, deciding instead to remain a publicly listed company. The company said the board did not receive a bid that reflected a premium to the company's trading price. Sciclone plans to continue with growth plans for its China-focused commercial business.
SHANGHAI – JW Biotechnology (Shanghai) Co. Ltd., a recently formed joint venture (JV) between Juno Therapeutics Inc. and Wuxi Apptec, will continue to develop CAR T treatments for Chinese patients, taking into account the learnings from the halted trials in the U.S. that resulted after three patient deaths.
SHANGHAI – JW Biotechnology (Shanghai) Co. Ltd., a recently formed joint venture (JV) between Juno Therapeutics Inc. and Wuxi Apptec, will continue to develop CAR T treatments for Chinese patients, taking into account the learnings from the halted trials in the U.S. that resulted after three patient deaths.
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd. is one of China’s most profitable non-state-run pharmaceutical firms focused on generics. With a market cap of $14.2 billion, last year Jiangsu Hengrui raked in revenues of $1.4 billion with a net profit of $327 million. But Chairman Piaoyang Sun saw the writing on the wall a few years back and has been preparing his company for an innovative future, one in which the U.S. plays a key role.
SHANGHAI – Singapore-headquartered Aslan Pharmaceuticals Pte Ltd. is deepening its ties to Taiwan. The oncology-focused biopharma has been growing its operational presence in Taiwan over the last three years, and is now making moves to go public there in 2017. In preparation, Aslan took on $23 million in series D financing from a group of local and global investors.
SHANGHAI – Singapore-headquartered Aslan Pharmaceuticals Pte Ltd. is deepening its ties to Taiwan. The oncology-focused biopharma has been growing its operational presence in Taiwan over the last three years, and is now making moves to go public there in 2017. In preparation, Aslan took on $23 million in series D financing from a group of local and global investors.
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd. is one of China's most profitable non-state-run pharmaceutical firms focused on generics. With a market cap of $14.2 billion, last year Jiangsu Hengrui raked in revenues of $1.4 billion with a net profit of $327 million. But Chairman Piaoyang Sun saw the writing on the wall a few years back and has been preparing his company for an innovative future, one in which the U.S. plays a key role.
SHANGHAI – Discovering and developing new drugs is hard anywhere in the world but perhaps especially so in China where it is a relatively new pursuit. For those who take on the challenge of bringing new drugs to market, now there is a place to share their woes and wisdom: the New Drug Founder's Club, or NDFC for short.
